SNDysregulation

SNDysregulation refers to a proposed dysregulation of the brain's monoamine systems—serotonin, norepinephrine, and dopamine—collectively abbreviated SND. The term is used in some neuroscience and psychiatry discussions as a framework to describe how imbalanced signaling among these neurotransmitters can contribute to a range of neuropsychiatric symptoms. It is not recognized as a formal diagnosis in major classification systems.

Mechanisms of SNDysregulation can arise from genetic variations affecting synthesis, packaging, release, receptor function, or transporter activity; epigenetic changes; chronic stress; neuroinflammation; or drug exposure. These factors can alter presynaptic release, receptor sensitivity, reuptake dynamics, and downstream intracellular signaling, leading to dysregulated activity in brain networks governing mood, motivation, attention, and executive function.

Clinical features are heterogeneous and may include mood instability, depressive or manic symptoms, anxiety, anhedonia, impaired concentration, and cognitive or motivational deficits. Because multiple monoamine systems are involved, symptoms may span affective, anxiety, and cognitive domains, with overlap across disorders.

Assessment and treatment rely on clinical evaluation and patient history; in research, biomarkers, pharmacogenomics, or neuroimaging are explored. Treatments aim to rebalance monoamine signaling and may include antidepressants, mood stabilizers, antipsychotics, stimulants, or novel agents, together with psychotherapy and lifestyle interventions. The field recognizes significant overlap with existing neurochemical theories, and SNDysregulation remains a conceptual framework rather than a standardized diagnosis.